UK patients turn on Roche to demand lower Kadcyla pricing
This article was originally published in Scrip
Executive Summary
A UK patient has set up a campaign to directly petition Roche to lower the price of breast cancer drug Kadcyla (trastuzumab emtansine), which UK health technology assessment authorities reluctantly refused to recommend as a result of the drug's £90,000 price tag.